The synthesis report follows the launch of the Belém Health Action Plan at COP30, a voluntary best practice framework to assist governments in adapting their health systems for climate change.

Nations worldwide must finance and implement climate adaptation measures for health systems or risk losing millions of lives as extreme weather, rising temperatures, and intensifying heat threaten healthcare access for nearly half the global population, according to a report published Friday by the World Health Organization and Brazil.

The special report, released at the COP30 summit in Belém, follows Thursday’s launch of the Belém Health Action Plan, which won backing from roughly two dozen countries but secured no financial commitments from governments.

The only funding to support the plan came from philanthropies: a $300 million one-time grant. The report estimates health system adaptation needs at $22 billion per year by 2035.

“The climate crisis is a health crisis – not in the distant future, but here and now,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “This special report provides evidence on the impact of climate change on individuals and health systems, and real-world examples of what countries can do – and are doing – to protect health and strengthen health systems.”

The past decade has been the hottest on record, with global temperatures exceeding 1.5°C above pre-industrial levels for the first time in 2024.

Updated Climate Tracker projections published at the UN climate summit on Wednesday show the world on track for 2.5°C of warming, while the UN Environment Programme projected last week that a business-as-usual scenario has the world heading for 2.8°C. Every fraction of a degree endangers millions.

“Many health systems are fragile, lacking climate-trained personnel, resilient infrastructure and adequate surveillance,” said Simon Stiell, executive secretary of the UN Framework Convention on Climate Change. “Watching super typhoons and flash floods rip through hospitals and local health clinics is heartbreaking, but lamenting is not a strategy. We need real solutions.”

Simon Still, executive secretary of the UNFCCC, addresses COP30’s opening plenary.

“The real challenges people face, such as extreme heat, air pollution, infectious diseases, mental health and food insecurity – humanity can only win this global climate fight if we connect stronger climate actions to people’s top priorities in their daily lives, and there are few higher priorities than our health,” Stiell said.

The report does not present new evidence, functioning instead as a synthesis of the best available science and data on the risks posed to unprepared health systems by climate change, drawing on academic literature, government and UN reports, and real-world case studies.

“Recent tragedies show that now is the time to implement policies and actions that address the impacts of climate change on health,” said Alexandre Padilha, Brazil’s health minister. “The Belém Health Action Plan and this report offer countries the tools they need to turn scientific evidence into concrete action.”

As storms batter coastlines, floods displace communities, and droughts fuel conflict and hunger, the report paints a picture of health systems under mounting strain. The familiar but alarming statistics form the case to policymakers to invest in adaptation and join the Belém plan.

More than 540,000 people now die annually from extreme heat, a 63% rise since the 1990s. Between 3.3 and 3.6 billion people live in regions highly vulnerable to climate change.

One in twelve of the world’s 200,000 hospitals face the risk of total shutdown due to extreme weather events under high-emissions scenarios, with more than 70% of at-risk facilities located in low- and middle-income countries. Hospitals and health facilities are also 41% more likely to suffer damage from extreme weather events than in 1990.

“Climate change is an unavoidable reality that challenges public health and adds pressure on already overwhelmed systems,” Padilha said, calling policies to protect the health sector one of the “most strategic decisions of the 21st century.”

“Protecting lives, reducing inequalities, and bolstering the resilience of health systems are no longer just goals – they have become ethical and democratic imperatives,” he said.

Mitigation left out of the main Belém text 

Brazil’s COP30 presidency chose the Amazon city of Belém in an effort to remind negotiators of the planet they are fighting to protect.

While the report and Belém Health Action Plan focus on preparing health systems for climate impacts, the synthesis document draws a clear conclusion about what would most protect those systems: cutting emissions.

“The evidence is clear: urgent and sustained mitigation across all sectors is the single most important health adaptation intervention,” states the executive summary. “There are profound physical, financial, and technological limits to adaptation, and health systems cannot remain resilient in a world of unchecked warming.”

By reducing emissions, health systems would face less extreme weather events, fewer heat deaths, and smaller disease burdens, making adaptation needs less severe in the first place.

That finding sits awkwardly with the Belém Health Action Plan itself, which contains no references to phasing out fossil fuels, the main driver of climate change.

The fossil fuel omission came at the explicit instruction of the Brazilian COP30 presidency, according to people familiar with the negotiations, likely to open the door for more nations to sign on who will not commit to language on fossil fuel phase-out.

What the report identifies as “the most effective measure” to protect health systems is excluded from the political Belém framework, which requires endorsement from governments, instead relegated to a supporting document with no political weight.

“When COP30 delegates leave Belém, success will be measured by the courage governments have demonstrated to act on what is already known: that fossil fuels are destroying people’s health,” said Jeni Miller, health lead at the Global Climate and Health Alliance. “To ignore these realities would be to betray both science and humanity.”

A $20 billion gap 

Adaptation needs for health systems estimated in the COP30 special report.

Direct health sector adaptation interventions will require more than $22 billion annually by 2035, according to the report, approximately 7% of total adaptation financing needs in climate-vulnerable countries.

Current health-specific climate finance reaching those countries totals around $500 to $700 million annually, representing 2% of adaptation funding and 0.5% of multilateral climate finance.

Climate and health finance has grown considerably in recent years, rising tenfold from less than $1 billion in 2018 to $7.1 billion in commitments between 2018 and 2022, according to analysis published earlier this year by the Rockefeller Foundation, WHO and other partners.

In 2022, this included $4.8 billion from bilateral donors, $600 million from multilateral development banks, $1.5 billion from multilateral health funds, and $130 million from philanthropies.

The share of climate finance targeting the health sector increased from 1% in 2018 to 9% in 2022, the only sector apart from education to see an increase. Yet these flows remain far below estimated needs, and more than 90% of health adaptation funding from development banks arrives as loans rather than grants.

“The evidence is clear that we have been too slow to act on climate change and we are now ill-equipped to cope with rising temperatures across the world,” said Alan Dangour, health and climate lead at the Wellcome Trust.

The report identifies persistent gaps in readiness. Only 54% of national health adaptation plans assess risks to health facilities. Fewer than 30% of health adaptation studies consider income, 20% consider gender, and less than 1% include people with disabilities. More than 60% of National Adaptation Plans have no formal tracking or evaluation in place.

“Extreme heat, air pollution and infectious disease all hit the most vulnerable hardest: children, pregnant people, older adults, outdoor workers, and communities with the fewest resources,” Dangour said.

“At COP30 and beyond, governments must act on the science – cut emissions, invest in adaptation, and put health at the heart of climate action. Lives, economies, and our future depend on the solutions we deliver now.”

Image Credits: COP30, COP30.

Child
Children’s health suffers in households where their mothers are abused.

Noma Bolani has a clear memory of her abusive father stopping the car in the middle of the highway in Durban, South Africa and asking her mother to get out. 

She was just six years old, but Bolani followed her mother out of the car, and together they sought help from a passing motorist. 

Bolani is now 38, and has anxiety stemming from early childhood experiences related to growing up with an abusive father and witnessing her mother being at the receiving end of emotional and financial violence.  

Ayesha*, 34, from New Delhi, India, grew up watching her mother being subjected to physical, emotional and financial violence from her father. He would sometimes also resort to silent treatment that would last weeks, refuse to pay school fees for Ayesha and her sister and resort to physical violence using belts, shoes and, at times, utensils.  

Ayesha suffers from Polycystic Ovary Disease (PCOD) that affects the regularity of her periods and causes hormonal changes. Her doctor believes the stress she was subjected to as a child played a significant role in worsening her PCOD.

Like Bolani, Ayesha also carries mental health scars from watching violence directed at her mother.

When mothers are at the receiving end of violence, it can make their children physically ill, according to a growing body of research. 

Impact on children’s health

Health data from 37 countries in sub-Saharan Africa found that children under the age of five whose mothers experienced intimate partner violence (IPV) were more likely to develop diarrhoeal disease and symptoms of acute respiratory infections, according to a study published in The Lancet last year.

It called for tailored interventions to address childhood morbidity and mortality attributed to IPV in “priority countries” – Burkina Faso, Burundi, Chad, Comoros, Gabon, Liberia, Nigeria, Sierra Leone, South Africa, and Uganda.

“The most important thing is actually the cumulative effect,” said Abel Dadi, lead author and a social epidemiologist at the Menzies School of Health Research at the Charles Darwin University in Australia.

His study looked at exposure to three kinds of violence – physical, sexual and emotional. “When they come together, their effect increases,” he said.

Dadi’s team also found a strong link between IPV and stunting in Burundi, and IPV and children being underweight in Burkina Faso, although the results were not consistent across all countries. 

What is not yet clear is the exact pathway of how IPV directed towards the mother affects a child’s physical health.

Maternal care
A mother and newborn at a health center in the Patna district of Bihar, India. Babies’ health and well-being is deeply affected by their mother’s health.

Pervasive violence

The World Health Organization (WHO) recognizes that violence against women is a major public health issue. Globally, one third (27%) of women experience IPV in their lifetime, according to WHO figures. In sub-Saharan Africa, these rates are even higher, with 45·6% of women experiencing IPV in their lifetime.

Young women aged 15 to 19 are the most affected by IPV. By the time they are 19 years old, almost a quarter of adolescent girls (24%) who have been in a relationship have already been physically, sexually, or psychologically abused by a partner, according to WHO data.

However, while it is widely accepted that intimate partner violence affects a woman’s mental, physical and sexual health at risk, its impact on children has not received the same attention. 

But a child’s health and well-being are completely dependent on their mother during pregnancy, and heavily dependent in the early years, so a mother’s health and well-being directly affects her child’s health.

The WHO, which developed a toolkit with UN Women to prevent violence against women in 2019, acknowledges that violence against women and against children often occurs in the same household. 

Psychiatrists like Bessel van der Kolk, who wrote ‘The Body Keeps the Score’, and Gabor Mate, author of ‘The Myth of Normal’, have also brought the lifelong impact of childhood trauma into the public domain, particularly of growing up with abusive parents.  

But IPV has long been seen as a criminal issue rather than a health issue. In India, for example, hospitals have only recently started to offer health workers training to see it as a public health problem.

“I don’t think it is a well-understood field of work in terms of a response from the courts or from the state’s response to children’s rights,” said Julie Thekkudan, South Asia consultant at Equality Now, a global non-profit that advocates for women’s and girls’ rights. 

Each dot represents a different country in the region.

There has been progress, with signs that IPV is reducing in some low- and middle-income countries due to progress in women’s empowerment.  

The reason women find it hard to leave abusive relationships, especially in the Global South, is that they have been socialized to tolerate violence, according to Thekkudan.

In societies that favour sons and devalue daughters, girls are socialized into believing that their “purpose in life is to get married”, she explained. Staying in a marriage, even if it is abusive, and seen as part of “making sure that your family honor is maintained”, Thekkudan added. 

That, in addition to the fact that women don’t always have the financial ability to leave, makes it a harder choice. 

Dadi said that any intervention design on maternal health should consider intimate partner violence as well as the mental health of the mother. Currently, most of these kinds of interventions are concentrated in high-income countries, according to research.

On average, countries that do better on gender equity indexes usually also experienc lower levels of violence against women, according to takeaways published in The Lancet.

But a woman’s higher economic status can also make her vulnerable. One study from sub-Saharan Africa showed that women’s employment, especially if they were the sole earners or if they earned more than their male partner, was linked to a higher level of intimate partner violence.

Any solution “has to be a multi-pronged, multi-level”,  said Thekkudan. “I don’t think there is one solution that will change the entire system or the structure.”

*Name changed to protect identity

Image Credits: Photo by Alex Pasarelu on Unsplash, BMGF, World Bank.

Belém framework wins backing from two dozen nations, but health remains outside formal UN climate negotiations.

Brazil launched a sweeping climate-health action plan on Thursday, named after the COP30 host city in the Amazon, winning initial endorsements from roughly two dozen countries for a voluntary framework calling on nations to strengthen disease surveillance, build climate-resilient infrastructure, and protect vulnerable populations from the health impacts of rising temperatures and extreme weather.

The Belém Health Action Plan outlines 60 action items across surveillance systems, evidence-based policies, and health innovation to address the health risks facing 3.3 billion people globally affected by the climate crisis.

“The climate crisis is one of the most significant health challenges of our time,” states the plan, developed by Brazil’s health ministry in consultation with the WHO. Countries that endorse the voluntary framework will report their progress through UN climate negotiations during the second Global Stocktake at COP33 in 2028.

The World Health Organization calls climate change “the greatest single risk to humanity,” and the World Bank estimates it could cause up to 15.6 million deaths between 2026 and 2050, with health impacts costing $8.6 to $15.4 trillion by mid-century.

Initial supporters include European Union states such as France and Spain, small island nations like Tuvalu, African countries from Congo to Zambia, and others including Canada, Japan, the United Kingdom and Malaysia.

Brazil’s health minister Alexandre Padilha said the plan had received backing from more than 80 nations and institutions, though the vast majority comprises civil society organisations like the Global Climate and Health Alliance, global health actors including Medicines for Malaria Venture and Drugs for Neglected Diseases Initiative, and UN agencies such as UNFPA, UNICEF and UNITAID.

“We expect to have more by the end of the day and the end of the COP,” Padilha said, adding the presidency would continue “trying to engage and mobilise” more countries. “There’s a very strong commitment from our government and ministers of health in this plan.”

Delegates gather in the plenary hall of COP30 in Belem for the launch of the Brazil-WHO-led health-climate adaptation plan.

The voluntary nature of the framework and broad support for the Alliance for Transformative Action on Climate and Health (ATACH) — a WHO-led initiative launched at COP26, which now counts 101 members — suggest endorsements will likely grow, but implementation remains uncertain. WHO will serve as the secretariat for the Belém plan, measuring outcomes through the ATACH framework.

The sole explicit dissent Thursday came from Egypt, part of the Baku coalition of previous COP presidencies that helped draft the plan. Egypt’s health minister expressed willingness to join but voiced “concern about the reference to the inclusion of LGBTIQ+ individuals, as such patterns fall outside the nationally recognised policy frameworks in the cultural context of Egypt.”

Other coalition members, the United Arab Emirates and Azerbaijan, expressed political will to continue discussions but stopped short of endorsement, instead noting they had “contributed” and “noted with interest” the framework’s goals.

“We have to look at the impact of climate change, one of the main threats to public health in the world today,” Padilha said. “Scientific evidence has shown clearly that the climate crisis is first and foremost a crisis of public health throughout the world.”

“The time of warnings has finished. Now we are living in a time of consequences,” he added. “The climate has already changed, so we have no alternative but to have public policies to adapt and face climate change.”

No money from nations

The voluntary adaptation framework was endorsed by around countries but faces billions in funding shortfalls.

The launch came with no new financial commitments from endorsing nations. The sole funding announcement came from a coalition of philanthropies including the Gates Foundation, Wellcome Trust, and Rockefeller Foundation: a $300m one-time grant to support climate-health adaptation measures.

That figure is dwarfed by estimates that low- and middle-income countries require at least $11 billion annually just for basic health adaptation covering only disease control for malaria, dengue, diarrheal diseases, heat-related mortality, and essential surveillance improvements, according to the UN Environment Programme.

“Health systems, already stretched and underfunded, are struggling to cope with these growing pressures, and most are still unprepared for what is coming,” said Marina Romanello, executive director of the Lancet Countdown at University College London. “Existing finance falls short by billions. Without urgent investment, we will not be able to protect populations from escalating climate impacts.”

The $11 billion annual UNEP pricetag excludes respiratory illnesses, malnutrition, mental health services, additional infectious disease programs, workers’ health protection, supply chain adaptation, and health system decarbonisation — most of what the Belém plan contains. The UNFCCC estimates global health adaptation will require $26.8 to 29.4 billion annually by 2050.

Current health-specific climate finance reaching those countries totals perhaps $500 to $700 million annually, representing 2% of adaptation funding and 0.5% of multilateral climate finance. “With regards to finance, that reality is that we have a deficit that is quite colossal,” said Carlos Lopes, Special Envoy for Africa to the COP30 Presidency.

A WHO survey of National Health Adaptation Plans found all included climate-health risks. But just 28 nations worldwide have completed such plans.

As temperatures continue rising and extreme weather events intensify, pressure mounts for health system adaptation at a moment when global health financing faces unprecedented strain. Overall development assistance for health dropped 21% from nearly $50 billion in 2024 to $39 billion in 2025, driven largely by US withdrawal from global health programs. The WHO itself faces budget shortfalls of 15-20%.

Climate-health financing has grown from less than $1 billion globally in 2018 to $7.1 billion in 2022, the only aid sector to grow in that time apart from education, according to Rockefeller Foundation analysis. But substantial portions arrive as loans: 24% of bilateral climate-health funding and more than 90% from the Asian Development Bank and Inter-American Development Bank.

Many developing countries now spend more on servicing debt than on healthcare, with low-income countries spending roughly 300 times less per capita on health than wealthy nations.

That finance shortfall impacts their ability to implement adaptation plans like the Belem Framework: A 2021 WHO survey found that while half of the countries reported having national health-climate strategies, less than a quarter achieved high implementation levels. Insufficient financing was identified as the key barrier by 70% of responding countries.

Health’s struggles mirror wider climate adaptation finance gaps. At COP26 in 2021, developed countries pledged to triple overall adaptation finance from 2019 levels to at least $120 billion per year by 2025. Actual flows across all sectors totalled $26 billion in 2023.

Money will determine whether Belém becomes an implemented plan or another symbolic declaration. Without tens of billions in annual funding, it will likely follow previous COP health commitments that failed to translate rhetoric into action.

“The Belém Health Action Plan gives us the blueprint,” said Simon Stiell, executive secretary of the UN Framework Convention on Climate Change. “What we need now is sustained, coordinated and well-financed action to turn its promises into protection for all.”

What’s the plan?

Launch event for the Belem Health Action Plan at COP30.

The Belém plan functions as a framework of best practice recommendations for adapting health systems to the climate crisis, containing no legally binding requirements or targets.

Instead, the document outlines recommendations organized around surveillance systems, policy interventions, and infrastructure overhauls that officials say are essential to protecting billions from climate-driven health crises. The one specific requirement: Countries that endorse it will report progress through the Paris Agreement’s Global Stocktake by COP33 in 2028, with no enforcement mechanisms or compliance requirements.

“For decades, WHO has been calling for action to adapt health systems and build resilience to climate change,” said Tedros Adhanom Ghebreyesus, WHO director-general. “The Belém health action plan is how we can do that.”

“Health systems themselves are affected by climate change, compromising their ability to deliver life-saving care when people need it most,” he said. “There can be no healthy people on a sick planet.”

The first focus: building the capacity to see threats coming. The framework calls for climate-informed health monitoring that links meteorological agencies with health institutions, using predictive modelling to trigger early warnings before heat waves, floods, or disease outbreaks overwhelm communities. Surveillance should also track which populations face the greatest risks, data officials say is often missing.

The second area addresses policy interventions to protect communities, including clean energy and sustainable transport, heat protection for workers, mental health support woven into climate response, and targeted measures for Indigenous peoples and persons with disabilities.

”For many countries, adaptation is a question of survival in the short run. If you don’t adapt, it threatens the coverage of health services of patients and professionals who are already facing adverse conditions,” Padhila said. “If we don’t adapt, we are going to increase inequality. In short, if you don’t adapt, we will kill people.”

Water & power

“It’s about the billions of people that we have the mandate here to make sure that we can change their lives, promoting health,” said Princess Abze Djigma of Burkina Faso.

Finance will determine whether the Belém framework’s most ambitious element, climate-resilient infrastructure, can be delivered.

The plan envisions health facilities built to withstand climate shocks, renewable energy powering clinics, telehealth platforms extending care, and strategic stockpiles of temperature-stable medicines and vaccines. It calls for “integrated methodologies linking environmental, meteorological, social, climate and health monitoring data” with real-time surveillance and digital technologies as “structural components.”

The problem: roughly 100,000 health facilities in sub-Saharan Africa lack reliable electricity, affecting nearly a billion people worldwide. Up to 70% of medical equipment in developing countries sits unused due to power failures.

Cold chains for vaccines, digital surveillance systems, early warning platforms, and telehealth services all depend on reliable power that serving populations don’t have. Closing the healthcare electrification gap by 2030 would cost $4.9 billion, about $5 per person affected over six years. That’s less than one year of current global climate-health spending.

“It’s about the billions of people that we have the mandate here to make sure that we can change their lives, promoting health,” said Princess Abze Djigma of Burkina Faso. “It is very important we have the policies… working on the value chains of electricity to make sure that our babies, who are getting born without electricity,” have access to care.

Water and sanitation infrastructure are equally critical, she noted. “If we bring water, we bring sanitation. There is already a disease that we will put away. We can tell our boys and girls to wash their hands, but how could they do it if there is no water at the school?”

Just three nations have completed all four ATACH assessments as of 2025.

The Belém plan’s success will depend not just on building infrastructure, but on countries’ ability to track and report progress. WHO will measure implementation through ATACH, its Alliance for Transformative Action on Climate and Health, which already requires members to complete vulnerability studies, adaptation plans, emissions inventories, and decarbonization roadmaps.

The record so far suggests those demands exceed many countries’ capacity. Four years after ATACH’s launch in 2021, only three countries—France, Japan, and the UK—have completed all four assessments. Across 88 countries with available data, roughly 35-40% completed vulnerability assessments and 30% finished adaptation plans. In Africa, fewer than 10 of 29 ATACH members have completed vulnerability assessments.

The Belém plan now adds reporting requirements on top of those existing gaps: tracking mental health impacts, monitoring workers’ heat exposure, establishing community resilience programmes, and climate-proofing supply chains, all by 2028.

That creates an impossible bind. France, Japan, and the UK have the technical capacity and resources to meet these demands. Many other countries lack not only the expertise for complex reporting systems, but the basic infrastructure, electricity and water, that the plan assumes as a foundation.

“Finance is still the bottleneck for us,” Princess Djigma said.

Fossil fuel phase-out excluded

Delegates arrive for the opening day of COP30 on the edge of the Brazilian Amazon.

Notably absent from the plan is any reference to phasing out fossil fuels, the main driver of climate change and the resulting heat, extreme weather and air pollution killing approximately 8m people annually from respiratory and cardiovascular diseases.

The omission came at the explicit instruction of the Brazilian COP30 presidency, according to people familiar with the negotiations.

The exclusion comes as the International Energy Agency warned Wednesday that global oil and gas demand will rise for the next 25 years if countries do not change course. Until this year, all of the Paris-based body’s modelling assumed fossil fuel consumption would peak this decade.

“Climate change is declining — and declining rapidly — in the international energy policy agenda,” said Fatih Birol, the IEA’s executive director. “And this is happening while 2024 was the hottest year in history.”

Fifteen countries allocated more resources to fossil fuel net subsidies than their entire national health budgets.

Birol’s findings align with the Lancet Countdown report published ahead of the summit, which found the 100 largest oil and gas companies have production strategies that put them on track to exceed their share of production consistent with 1.5 °C of heating by 189% in 2040, up from 183% in March 2024.

Private bank lending to fossil fuel activities surged 29% to $611 billion in 2024, exceeding green sector lending by 15%. Some 73 of 87 countries reviewed provided net explicit fossil fuel subsidies in 2023, allocating nearly $1 trillion in direct support. Including indirect subsidies, that figure rises to over $7tn, according to the International Monetary Fund — more than governments spend annually on education and about two-thirds of what they spend on healthcare.

The declining political attention extends to international engagement: Mentions of health and climate change by governments in their annual UN General Assembly statements declined from 62% in 2021 to 30% in 2024, according to the Lancet Countdown.

“Record deaths from climate-driven wildfires in 2023 show that there’s no adaptation without mitigation,” said Nina Renshaw, head of health at the Clean Air Fund. “Ministries of Health and Finance won’t be able to bail hospitals and clinics out of the climate emergency if governments don’t stop the emissions which are already causing unprecedented harm.”

‘More than dialogue’

Delegates convened for the first-ever Health Day at a UN climate summit in Dubai.

The Belém plan follows a pattern established at recent climate summits: the COP28 Dubai Health Declaration signed by 143 countries, the Baku Coalition for Climate and Health launched last year, and efforts stretching back to Glasgow in 2021. Like those efforts, Belém is a non-binding, voluntary process taking place outside formal UN negotiations.

Criticisms of the outcomes of Dubai and Baku describe their outcomes as symbolic gestures that generate attention but fail to secure funding, sustained commitment, or implementation. Officials on Thursday repeatedly stressed the need to break the holding pattern.

“This gathering must be more than dialogue,” said Jarbas Barbosa, director of the Pan American Health Organization. “It must galvanise collective action and inspire new policies dedicated to protecting everyone’s health from the worsening effects of climate change.”

“The climatic crisis is fundamentally a health crisis,” Barbosa said. “We are not talking any more about distant or possible threats. Climate change is a present and growing reality.”

Whether the Belém framework can overcome the obstacles that have stymied previous declarations — insufficient financing, limited technical capacity, competing priorities — remains uncertain. But Padilha argued the world has no choice but to try.

“We are faced with a dilemma: we either continue to speak and speak and talk, or we can walk the walk and make the political commitment to do so,” he said. “We cannot accept the erosion of multilateralism in global health. Those who deny multilateralism are surrounding us. We will not listen to them.”

Image Credits: COP30, COP30, COP30, COP30, COP30, COP30, WHO .

Andrew Black, Acting Head of the Secretariat of the WHO FCTC, and Reina Roa, President of the COP11, at the opening press conference.

GENEVA – Global health leaders are calling for robust new measures to combat the use of tobacco and related products, including restrictions on flavours to curb the surge in e-cigarettes use in adolescents and filter bans to protect the environment. 

These and other proposals will be debated over the next two weeks as over 1,400 delegates representing governments, international organisations and civil society gather in Geneva for the World Health Organization’s (WHO) Framework Convention on Tobacco Control (FCTC).

“The meeting will bring the world together to energize international cooperation and foster political will to address the global tobacco epidemic. Well over seven million people die each year because of tobacco,” said Andrew Black, acting head of the WHO FCTC Secretariat, at the opening press conference for the 11th Conference of Parties (COP11). 

The FCTC provides a binding legal framework and a package of control measures for the parties. Since it came into force 20 years ago, significant progress has been made. Today, over 75% of the global population – more than 6.1 billion people – are covered by at least one of the WHO’s MPOWER tobacco control measures, which are a set of cost-effective technical recommendations designed to reduce tobacco use.

“Since the FCTC came into effect, tobacco use has declined by a third worldwide, despite the tobacco industry’s efforts to undermine it,” noted WHO Director-General Dr Tedros Adhanom Ghebreyesus.

New products undermine successes

But this progress is facing increasing challenges as the tobacco industry markets new nicotine products such as e-cigarettes, heated tobacco products and nicotine pouches – all of which are now widely available in many countries.

Data presented by the WHO shows that, on average, e-cigarette use among adolescents aged 13 to 15 is nine times more prevalent than among adults in the same country.

Health bodies and researchers claim that the industry’s focus on sweet and fruity flavours, bright packaging and social media promotion is designed to attract young consumers.

The regulation of these new products is lagging. By the end of 2024, 62 countries still had no policy in place regarding electronic nicotine delivery systems (ENDS) and 74 countries had no minimum age for purchasing e-cigarettes. Only seven countries ban all characterising flavours in ENDS, excluding those that prohibit sales entirely.

Call for ban on filters, debate on flavours

The FCTC will address the obligation of parties to prevent and reduce nicotine addiction for the first time, said Kate Lannan, senior lawyer to the Secretariat of the WHO FCTC.

The COP11 agenda includes robust regulatory proposals. High-level discussions are expected on extending existing regulations or bans on flavours across all products and member countries, and on holding the industry legally responsible for causing harm to public health.

“This is the first time the conference of the parties will be specifically addressing the obligation of parties to prevent and reduce nicotine addiction,“ said Kate Lannon, senior lawyer at the WHO FCTC Secretariat, with regard to evolving nicotine addiction among young people.

Protecting the environment will also be a focus. There are growing concerns over cigarette filters, which are made of cellulose acetate, a type of single-use plastic. The WHO and several member states, including the Netherlands, are urging parties to consider banning filters altogether. 

They argue that this would reduce toxic pollution and address the misconception among consumers that filters substantially reduce health risks. 

“These filters on cigarettes don’t provide any meaningful increase in the safety of cigarettes,“ explained FCTC’s Secretary Black.

Delegates will also discuss implementing a levy for environmental damage or establishing Extended Producer Responsibility (EPR) measures to collect funds to mitigate environmental harms across the entire tobacco product life cycle. Negotiations on increasing taxes on tobacco products are expected to continue.

Industry interference is the biggest barrier to regulation

Tobacco industry interference has become more aggressive, according to the Global Tobacco Industry Interference index (GII), with countries like the United States, Switzerland and Japan among the worst regulated.

Industry interference is reported as the “biggest constraint and barrier” to implementing the Convention. According to the 2025 Global Tobacco Industry Interference Index (GII), the industry is becoming “increasingly aggressive” in its tactics. 

These include “harm reduction” narratives, targeting non-health departments (like finance and trade), “political capture” of delegations, and using “greenwashing” tactics – such as funding tree planting or cigarette butt clean-ups – to improve its public image and gain access to officials.

According to the University of Bath’s monitoring organisation, Tobacco Tactics, the World Vapers’ Alliance (WVA) is funded by the tobacco industry. The WVA has argued against flavour bans and tax increases, claiming that they disregard the needs of adult vapers.

In response, the FCTC Secretariat has urged all parties to fully implement Article 5.3, a legal clause requiring governments to protect their public health policies from industry interests.

Public health analysts suggest that failure in tobacco control is rooted in industry interference and a lack of political will, not a lack of regional capability or money. 

For example, while the European region is set to miss its 2025 reduction target, the Netherlands maintains one of the lowest levels of industry interference globally.

Meanwhile, Ethiopia, a low-income country, ranks fifth best in the Global Interference Index, using robust legal protections and strong cross-government coordination to build a resilient system against industry interference.

Image Credits: Felix Sassmannshausen, Stop Tobacco.

Cholera oral vaccine Sudan
A child gets an oral cholera vaccine.

South Africa aims to become the first African country to manufacture a cholera vaccine with the launch this week of a clinical trial of an oral vaccine developed by local company Biovac.

The vaccine candidate was developed thanks to a technology transfer partnership between Biovac and the International Vaccine Institute in South Korea in 2022.

At present, the only manufacturer of a cholera vaccine is EuBiologics in South Korea, which makes a vaccine marketed as Euvichol-Plus.

This has severely constrained the global supply of cholera vaccines, leading to rationing and global shortages as cholera outbreaks have surged worldwide, spurred by waves of climate-related weather crises and conflict, particularly in Africa.

This week, Biovac announced the launch a Phase 1 safety trial of the vaccine at the University of the Witwatersrand in Johannesburg.

If the vaccine is deemed safe, in the larger Phase 3 study, the Biovac Oral Cholera Vaccine will be compared to Euvichol-Plus, EuBiologics vaccine.

The only cholera vaccine in the world is made by South Korea’s EuBiologics. Biovac was assisted in developing its vaccine by a technology transfer agreement with the International Vaccine Institute in South Korea.

“Biovac is proud to be manufacturing this vaccine entirely in South Africa, the first time in over fifty years that such a milestone has been achieved,” said company CEO Dr Morena Makhoana.

Biovac has evolved from a vaccine distributor to a” full-scale manufacturing hub”, the company noted in a statement.

“Vaccines manufactured in South Africa usually receive the active pharmaceutical ingredient from abroad, with the final vaccine being completed in South Africa (often referred to as ‘fill and finish’), but in this case, the vaccine candidate is being manufactured from start to end by Biovac,” the company added.

“If the trials are successful, South Africa will become the first country on the continent to produce a cholera vaccine,” Makhoana said. “This development addresses a critical, life-saving need, given the ongoing global shortages of the vaccine amid recurring cholera outbreaks.”

Depending on the trial outcomes, the vaccine could be approved and ready for use in Africa in 2028.

Enhanced health security

South African Minister of Health, Dr Aaron Motsoaledi, described the trial as “a historic milestone, not only for Biovac and our nation, but for the entire continent”. 

“Building local vaccine manufacturing capability is not a luxury; it is a national necessity. It strengthens our sovereignty, enhances our health security, and ensures that our people are not left behind when the next global health crisis strikes,” said Motsoaledi. 

“When we can research, develop, and manufacture vaccines locally, we reduce our vulnerability to supply chain disruptions, geopolitical pressures, international market competition and vaccine hoarding or vaccine nationalism, which was apparent during the height of COVID-19 pandemic.”

The African Union has set a target for 60% of all routine vaccines used in Africa to be manufactured on the continent by 2030, a major advancement from today’s level of less than 1%.

Gavi, the Vaccine Alliance, has put incentives in place for African-made vaccines, putting Biovac in a strong position to secure market share and making it a frontrunner in the bid to sell the vaccine to African countries and those who need it.

Gavi’s African Vaccine Manufacturing Accelerator (AVMA) will make up to $1 billion available over the next 10 years to support the growth of Africa’s medicines and vaccines manufacturing base.

The Biovac vaccine development project is supported by the Gates Foundation, Open Philanthropy, Wellcome, and the ELMA Vaccines & Immunization Foundation, among others.

Florian von Groote, Wellcome’s head of clinical research (infectious disease), said that the trial “could be a major step in strengthening the African vaccine manufacturing landscape, showing that local manufacturers can make vaccines that meet the needs of communities on the continent.

“Through long-term support and investment, local manufacturing can deliver accessible and affordable vaccines made by Africa, for Africa.” 

Image Credits: WHO.

London heat wave in June 2024; climate change has triggered more extreme heat events, and related mortality, in rich and poor countries alike.

A $300 million investment in projects integrating health into climate action has been announced at the UN Climate Conference in Bélem, Brazil by a coalition of “Climate and Health Funders Coalition” which includes over 35 of the world’s leading philanthropies and foundations, including Rockefeller, Gates and Wellcome. 

This announcement was made at the high-level opening of the COP30 Health Day – where a new Bélem Health Action Plan was launched. The Action Plan aims to thrust climate adaptation for the health sector more squarely into the centre of climate actions and tracking, making it part of the global stocktaking exercise. 

“Adaptation is a question of survival in the short run,” declared Brazil’s Minister of Health,  Alexandre Padilha, while launching the Action Plan. “The most recent Lancet Countdown Report on Climate and Health is clear – 3.3 to 3.6 billion people live in highly vulnerable climate areas – and hospitals [in those areas] face a 41% risk of suffering from extreme weather events.

Alexandre Padilha, Brazilian Minister of Health, at COP30 Health Day

“If you don’t adapt, it threatens the coverage of health services of patients and professionals who are already facing adverse conditions. If we don’t adapt, we are going to increase inequality. In short, if you don’t adapt, we will kill people,” he added.

The funding coalition aims to “accelerate solutions, innovations, policies and research on extreme heat, air pollution and climate-sensitive infectious diseases,” the partners said in a press release Thursday. 

While the $300 million commitment may be a drop in the bucket of needs, the aim is to expand the fund, coalition members told Health Policy Watch:

“It is just initial funding and we intend to bring in more philanthropies in the year ahead as well as work with other sectors to significantly increase funding for climate and health solutions,” said Garth Davies, a spokesperson for Wellcome.

See related story: Brazil Wins Limited Backing for COP30 Climate-Health Plan, But Nations Commit No Finance

COP30 is currently underway in Brazil’s Amazon region city of Belém.


“The warnings from scientists on climate change have become reality. And, it is clear that not all people are affected equally”, said John-Arne Røttingen, Wellcome CEO. “The impacts of rising temperatures hit the most vulnerable people hardest – children, pregnant people, older people, outdoor workers and those communities with the least resources to respond. Every country in the world is now affected by climate change, and we need to develop and implement solutions fast to save lives and livelihoods.” 

“Every person should have the opportunity to live a healthy, productive life, no matter where they were born,” said Steve Davis, Senior Advisor for Philanthropic Partnerships at the Gates Foundation. 

“But a hotter world with less predictable and more extreme weather is threatening that vision for the future, particularly for people in low- and middle-income countries. Philanthropy has a unique role to play in contributing flexible funding to accelerate innovative solutions that protect health and help communities build resilience to climate shocks,” he said. 

Other big names in the development sector that have signed onto the coalition plan include: Bloomberg Philanthropies, Children’s Investment Fund Foundation, IKEA Foundation, Quadrature Climate Foundation, and Philanthropy Asia Alliance.

Climate data and heat adaptation 

Women in Bangladesh queue for drinking water in the southwestern coastal region, facing increased saltwater intrusion linked to storm surges and sea level rise that climate change has worsened.

The Coalition’s funds are aimed to “support” the Bélem Health Action Plan through funding of projects on the ground, Davies said, citing projects on: adaptation to extreme heat in India, collecting climate and weather data in Africa, and combating air pollution, whose emissions also contribute to climate change: 

“In extreme heat, one example organization the Coalition is supporting is the Indian nonprofit Self-Employed Women’s Association (SEWA). SEWA is the largest movement of informal workers in India – and one of the largest in the world – with over 3.2 million members. SEWA works to address the threats that extreme heat poses to health and livelihoods.”

Another project receiving support is The African Centre of Meteorological Application for Development (ACMAD). It is the primary pan-African centre working to collect, analyze, and disseminate weather and climate data across the continent, supporting national meteorological agencies and governments in all 53 African countries.

“By coming together to align our priorities and combine our resources, this coalition can accelerate solutions faster, reach more communities, and achieve greater impact. This is the power of collaboration: recognizing the urgency of the challenge and working as one to protect lives, strengthen health systems, and build resilience for communities around the world,” said Naveen Rao, Senior Vice President of Health at The Rockefeller Foundation, in the press release.

Making the Bélem COP, a health COP

Through the Belém Health Action Plan, officials want to make this COP, a “health COP.”

Brazilian authorities have long said that they hope to make this COP a “health COP” – after it played a largely backstage role at COP29 in Azerbaijan. COP28 featured the first Health Day at a UN Climate Conference, with high-powered speakers like Bill Gates and then-US Climate Envoy John Kerry on the podium.  

While the health impacts of climate change have been intensifying, health has, however, remained on the fringes of mainstream COP debates and decisions. 

It remains to be see if the Belém Health Action Plan can win widespread political buy-in and finance to empower countries to make health a more central element in their climate action agendas in the health sector.  

Along with “adaptation”, however, the massive health benefits of mitigating climate change in other sectors from transport to energy production and housing, have yet to be formally recognized by climate negotiators – benefits that could save tens of millions of lives across the coming decade, through reduced heat exposures, less air pollution, and more physical activity as well as healthier diets and food security.  

“The health consequences of climate change are mounting, and they fall hardest on communities least equipped to respond. By supporting the Climate and Health Funders Coalition, we’re working to build health systems that are resilient, equitable, and prepared for the challenges ahead,” said Jess Ayers, CEO of the Quadrature Climate Foundation.

Image Credits: Abir Abdullah / Climate Visuals, Alastair Johnstone / Climate Visuals, X/@Cop30noBrasil, X/@Cop30noBrasil.

GanLum Phase 3 trial results presented at ASTMH annual conference in Toronto. From right to left: David Fidock, American Society of Tropical Medicine; George Jagoe, MMV; Ruairidh Villar, Novartis; Sujata Vaidyanathan; Novartis; Abdoulaye Djimdé, University of Sciences Techniques and Technologies, Bamako, Mali.

The 97% cure rate for the novel compound, ganaplacide/lumefantrine in a recent Phase 3 trial offers hope for continued progress rolling back malaria even as resistance to artemisinin combination therapies (ACT) escalates. 

A next-generation antimalarial drug GanLum (ganaplacide/lumefantrine, KLU156) slightly outperformed a standard of care Artemisinin Combination Therapy (ACT) in a recent Phase 3 trial – offering new hope that recent gains against malaria can be maintained and advanced despite growing parasite resistance to current treatments.  

The randomised controlled trial (RCT) involving over 1,600 participants across 12 Sub-Saharan African Countries demonstrated a +97% cure rate for GanLum, as compared to 94% for the ACT, Coartem©, in the control arm of the trial, said the pharma firm Novartis. The results were published Wednesday following an embargoed briefing at the annual conference of the American Society for Tropical Medicine and Health (ASTMH) in Toronto, including Novartis co-developer, Medicines for Malaria Venture (MMV), lead trial coordinator, Abdoulaye Djimdé, and ASTMH President, David Fidock. 

The trial is all the more significant insofar as it tested efficacy against malaria caused by the most deadly parasite, Plasmodium falciparum (P. falciparum).

The Phase 3 trial results confirm the efficacy as well as safety of GanLum.

P. falciparum is responsible for almost all malaria-related deaths worldwide. African countries bear the heaviest burden, accounting for an estimated 95% of the 597,000 malaria-related deaths globally in 2023.

After falling dramatically from 2000 to 2015, malaria deaths and infections, which mainly occur in children under 5 years old, have increased. The 2023 levels of 263 million cases and 597,000 deaths reflect the sharp rise seen since 2016 when there were 216 million malaria cases and 445,000 deaths.

“GanLum could represent the biggest advance in malaria treatment for decades,” declared  Djimdé, Professor of Parasitology and Mycology at the Bamako University of Science, Techniques and Technologies in Mali. Djimdé coordinates the West African Network for Clinical Trials of Antimalarial Drugs (WANECAM), which was a lead partner in the GanLum trial. The trial, which included 34 sites across West and Central Africa along with others in Zambia, Kenya, Uganda, Tanzanina, and one site in India, began in March 2024 and concluded in June 2025. 

“After the successful Phase 3 trial, we will submit the drug for regulatory approval as soon as possible,“ said George Jagoe, Executive Vice President at Medicines for Malaria Venture (MMV), the Geneva-based non-profit product development partnership. “We hope to see it within a year, year and a half, in the hands of countries and eventually in patients.” 

Volunteer healthworkers collect supplies during a seasonal malaria chemoprevention campaign in Nigeria.

Initial regulatory approval is expected to be sought in Switzerland via Swissmedic. But the aim is to kickstart national regulatory procedures in the Sub-Saharan Africa region as well, added Vaidyanathan.

The drug would be made available on a ‘largely not-for-profit’ basis in low- and middle-income countries, MMV said, in accordance with agreements signed with Novartis.

The next-generation drug GanLum combines the novel non-artemisinin compound ganaplacide (KAF156), with an updated formulation of lumefantrine (LUM-SDF), also used in standard ACTs. Ganaplacide was initially identified by Novartis through high-throughput screening of 2.3 million compounds in San Diego, California, funded by MMV and the Wellcome Trust.

Together, the components target multiple stages of the malaria parasite’s life cycle and can prevent transmission. Ganaplacide disrupts the parasite’s internal protein transport system, which is essential for its survival inside red blood cells. It is also effective against the mature sexual stages of the parasite (gametocytes), as explained by Sujata Vaidyanathan, Head of the Global Health Development Unit at Novartis. 

This blocks them from spreading to other human hosts via mosquito bites. Meanwhile, lumefantrine prevents the parasite from re-emerging in the human’s body at a later stage.

Trial confirms efficacy and safety

A doctor at a district hospital in Ifakara, Tanzania treating a malaria patient. Nearly 600,000 people annually still die from the disease, mostly in Africa.

The trial involved randomised testing of the GanLum against the control drug Coartem©, a gold standard for treatment,  on 1,688 adults and children weighing at least 10 kg and aged at least two years with acute, uncomplicated malaria, across 34 sites in the 12 African countries where it was tested.

The primary objective of the Phase 3 trial was to demonstrate that KLU156 is non-inferior to Coartem© (artemether-lumefantrine), as measured by the PCR-corrected cure rate on day 29 of treatment. 

According to data provided by Novartis, GanLum achieved an efficacy of 97.4% using the “estimand” framework. The current standard of care with ACTs has a rate of 94%. The “estimand” method is a conservative approach to results, required to support regulatory submissions, which considers patients that discontinue the study or for whom PCR data is missing at the time of the primary analysis to have failed the treatment.

Regarding the side effects, expert Djimdé said: “As with any drug, there are certain expected side effects. However, this was a randomised trial, and the safety profile is comparable to that of the reference compound. So it is absolutely fine to be put in the hands of patients.”

Hope in face of drug resistance and funding cuts

Mapping of parsasite resistance to artemisin, the key active ingredient in component in ACTs.

This new drug combination is a vital advance in the fight against malaria. Progress had recently stalled due to global health funding cuts and the conflict-linked displacement of many malaria-prone populations. In addition, extreme weather events caused by climate change have damaged public health infrastructure and enabled malaria parasites to spread to new regions.

The emergence of partial resistance to artemisinin-based combination therapies (ACTs), threatens to undo years of progress. According to the WHO, this could result in an additional 78 million malaria cases over five years in a business as usual scenario.

MMV’s Jagoe described reports of resistance in several countries in Central and Eastern Africa, such as Rwanda and Uganda, as “smoke signals’’, adding. “It is a huge relief that we can now think about a brighter future,“ he said. “We finally have a fire extinguisher ready.”

The intention is not to abandon artemisinin-based treatments, but rather to add an effective new weapon to the fight against malaria. 

Significantly, GanLum also targets mutations of the parasite that are markers of drug resistance.

Crucial step in long road toward elimination 

Animation of the ganaplacide molecule that is a key component of the novel antimalarial combination drug GanLum.

The experts presenting the Phase 3 trial results described tremendous excitement over the results – a crucial step forward in the fight against malaria. 

“I’m very, very excited, and very pleased to see the results of this GanLum trial”, said Jagoe from MMV.

However, after approval, the drug will still have to prove its efficacy in the field.

Challenges to overcome

And there are major challenges to overcome. The trial was initially designed to include children weighing over 5 kg and aged over two months. 

That is because infants and toddlers, especially those in the lowest weight category, typically have the highest mortality rates, particularly in areas with moderate to high transmission rates.

However, since reported prevalence is often lower, the age, and weight thresholds of the trial were increased in a pragmatic move to identify trial participants and accelerate the process of testing the new drug.

But the intention is to trial the drug on children between 5 and 10 kg in weight and 2 months and 2 years in age – as soon as it becomes feasible.

As a Novartis spokesperson explained in an interview with Health Policy Watch, “We are committed to supporting the youngest children.” 

Novartis recently received approval for Coartem Baby, a malaria drug designed for newborns and young infants, also co-developed with MMV.

See related story here. 

Ghanaian Newborns First to Get New Malaria Medication

While the road to a single-dose curative treatment for malaria, often referred to as the Holy Grail, remains elusive, GanLum also represents a step forward on that score. It is administered as a daily sachet of granules for three consecutive days. Standard antimalarial therapy with ACTs involves taking medication twice daily for three days.

This complex regimen is known to result in suboptimal patient adherence – wiith a third or more of patients failing to complete regimes in the real-world. This reduces the effectiveness of the drug and increases the likelihood of partial resistance.

A potential single-dose treatment, also unveiled at the ASTMH, could significantly improve adherence as well as fighting parasite resistance, its proponents say.  The single-dose treatment combining four known anti-malarials –  sulfadoxine, pyrimethamine, artesunate and pyronaridine (SPAP) — was trialed on 539 patients in Gabon with uncomplicated malaria, including children under the age of 10, as compared to another 442 people who received the standard ACT. Some 93% of patients who received the single dose cure were free of parasites after 28 days, as compared to 90% of those who received the standard ACT.  

“We found that our single-dose treatment was just as effective as the standard course that typically requires taking six doses spaced out over three days, which many patients never complete,” said Ghyslain Mombo-Ngoma, MD, PhD, lead author of the study and head of clinical operations at the Medical Research Center of Lambaréné, Gabon (known by its French acronym CERMEL).

Image Credits: Novartis, Health Policy Watch , Novartis , Munira Ismail_MSH, Peter Mgongo, WHO .

A tuberculosis patient in Mozambique celebrates completed her treatment with a community health worker sponsored by USAID funds, which has since been slashed.

Last year, the global battle to reduce tuberculosis infections and deaths showed small signs of recovery following three disruptive COVID-19 years – but this year’s precipitous drop in development aid is likely to cause new setbacks, according to the World Health Organization (WHO).

TB killed 1.23 million people in 2024 and made 10.7 million people sick in 2024, according to the Global TB Report 2025 released by the WHO on Wednesday (12 November).

There was a tiny 3% decline in deaths and a 1% decline in new infections last year in comparison to the previous year.

But the impact of the precipitous drop in development aid, particularly from the United States since January, is not reflected in the report, which tracks data from 2024, noting only that: “Cuts to international donor funding from 2025 onwards threaten overall funding for the TB response in many countries.” 

Speaking at a WHO press conference Wednesday, Director General Dr Tedros Adhanom Ghebreyesus described as “good news” the decline in new TB cases and deaths. “Meanwhile, the number of people being tested and treated is increasing and research is advancing for the first time in over a century. New effective TB vaccine for adolescents and adults are within reach,” Tedros said, noting that 18 vaccine candidates are currently in clinical development, including six in Phase 3 trials.

“Despite all this good news… TB still killed more than 1.2 million people in 2024 which for a disease that’s preventable and curable is simply unconscionable,” Tedros said, adding that, “funding cuts to international aid in many low and middle income countries threaten to reverse the hard won gains we see.

“It’s therefore vital that countries step up domestic resource allocation, alongside international funding.”

Just eight countries account for 67% of TB cases: India (25%), Indonesia (10%), the Philippines (6.8%), China (6.5%), Pakistan (6.3%), Nigeria (4.8%), the Democratic Republic of the Congo (3.9%) and Bangladesh (3.6%).

‘Concerning trends’

WHO TB director Dr Tereza Kasaeva.

The WHO has already seen “some concerning trends” for  2025, particularly in the highest burden, low- and middle-income countries (LMICs) that have been “heavily dependent on international donor funding”, said Dr Tereza Kasaeva, WHO director for HIV, TB, Hepatitis and STIs.

These include disruptions to access to TB treatment, diagnosis and prevention; problems with monitoring and reporting, drug delivery, sample transportation, and “one of the biggest impacts”, community engagement, she told a media briefing before the launch.

The report notes that estimates of the impact of the funding cuts, particularly by the US, include “about half a million additional deaths and 1.4 million additional cases in the period 2025–2035 if USAID funding is not replaced, increasing to about two million additional deaths and five million additional cases when cuts in contributions to the Global Fund are also considered”.

Least progress made in funds mobilisation

Even before the funding cuts, progress in achieving TB goals fell far short of global targets. The worst-performing targets for 2024 relate to funds mobilisation.

Only $5.9 billion of 2027’s $22 billion target for TB treatment had been collected, and slightly more than 20% of the $5.5 billion research target for 2027 has been achieved.

Despite the lack of resaerch funds, the WHO notes that development pipeline is strong.

“As of August 2025, 63 diagnostic tests were in development and 29 drugs were in clinical trials – up from just eight in 2015. Additionally, 18 vaccine candidates are undergoing clinical trials, including six in Phase 3.”

Drop in deaths

Since 2015, there has been a 29% drop in deaths – but the target was a 75% reduction by this year. 

However, two WHO regions have done substantially better than the global average: Europe, which cut deaths by 49% by 2024; and Africa, with a 46% reduction in deaths, mainly as a result of better outcomes for people coinfected with HIV.

Similarly, there has only been a 12% drop in TB incidence against a global target of 50% between 2015 and 2025. However, Europe achieved a 39% decrease and Africa, a 28% decrease.

In contrast, TB incidence has risen by 5% or more in Indonesia, Myanmar and the Philippines. 

Meanwhile, 47% of households with people living with TB face “catastrophic” health costs against a target of zero.

However, Kasaeva noted that 8.3 million people who were newly diagnosed with TB in 2024 accessed treatment, “representing about 78% of the people who fell ill with the disease during that year”.

In addition, the coverage of rapid testing for TB diagnosis increased from 48% in 2023 to 54%, while there was an 88% success rate for “treatment for drug-susceptible TB”.

Building sustainable systems

Dr Yogan Pillay, Gates Foundation’s director for HIV and TB.

However, Dr Yogan Pillay, Gates Foundation’s director for HIV and TB delivery, said that several countries were “stepping up, both in increasing domestic financing and looking at other ways of delivering services” since the cuts in aid.

He singled out Indonesia, Nigeria and South Africa for upping domestic financing for TB in the wake of cuts to global health financing.

“That’s what we need to focus on now. How do we develop systems that are sustainable, including in low and middle-income countries?” Pillay asked.

“We need to change the ways in which we do things so that we can sustain the gains that we’ve seen in the 2024 data, notwithstanding any funding cuts.”

A significant proportion of the TB burden is driven by five major risk factors: undernutrition, HIV infection, alcohol abuse, smoking and diabetes, according to the report.

“Tackling these issues, along with critical determinants like poverty and GDP per capita, requires coordinated multisectoral action,” according to the WHO.

The report concludes by noting that, in the face of cuts to international donor funding from 2025, “political commitment and domestic funding in high TB burden countries are more important than ever”.

Image Credits: Arnaldo Salomão Banze, ADPP Mozambique.

Ghana’s President John Mahama welcoming delegates to the Africa Health Sovereignty Summit

In August, African leaders gathered in Accra, Ghana, to chart a path for the continent’s future in public health. Their message was unequivocal: Africa’s political independence is incomplete without the power to shape its own development – including the health of its people. 

The Africa Health Sovereignty Summit was a demand to break free from the dependency that has stunted the continent’s ability to safeguard the health of its own people.

History shows why these matters. At the height of the AIDS crisis, lifesaving drugs reached Africa only years after they were standard in the West, costing countless lives to a treatable virus. 

During the COVID-19 pandemic, wealthy nations stockpiled vaccines in excess – even for low-risk groups – while African countries scrambled to secure doses for their most vulnerable. 

It was a stark reminder that the self-interest of the rich can override the basic needs of the poor.

International funding has played a pivotal role in advancing Africa’s health. From the Global Fund to the US President’s Emergency Plan for AIDS Relief (PEPFAR), to GAVI, external support has not only saved lives but also improved livelihoods, extended life expectancy, and strengthened economies. 

Inequities in global health architecture

Biden-era US officials hand donated mpox vaccines to Nigerian health officials.

That solidarity deserves recognition, but it must be retooled to truly serve Africa. Today, many inequities remain embedded in the current global health architecture. Investment frameworks are typically drawn up in Geneva or Washington, rather than in Accra or Nairobi. Funding rises and falls with the politics of donor nations.

That imbalance also shapes perception. Our continent of 1.4 billion people – dynamic, youthful, and skilful – is still too often seen as a recipient of charity. 

Even when African scientists lead, as South African researchers did by sequencing the COVID-19 variant called Omicron, they are treated as recipients rather than equal partners. That not only limits Africa’s potential but also leaves the whole world more vulnerable to the next pandemic.

The way forward is clear: Africa must invest in its own health with the same urgency it devotes to infrastructure, defence, or governance. Healthy citizens are the foundation of innovation, stability, and prosperity. Each dollar invested in health paves the path to wealth, multiplying productivity and resilience.

New kind of solidarity

Dr Muhammed Ali Pate addressing Nigeria’s high-level national policy dialogue on reimagining the future of health financing.

Some governments are charting the path forward. Last month in Nigeria, we convened a high-level national policy dialogue on reimagining the future of health financing. The initiative brought together government officials, development partners, civil society, academia, and the private sector to design sustainable approaches to financing healthcare for all in Nigeria.

This builds on Nigeria’s leadership in advancing universal health coverage (UHC). In the Abuja 2001 Declaration and the Abuja+12 Declaration, member states pledged to increase domestic financing for health to build stronger and more self-reliant health systems.  

At the 78th World Health Assembly this year, countries adopted a Nigeria-sponsored initiative aimed at strengthening global health financing and accelerating progress toward long-standing commitments to achieve UHC.

The message from Accra and Abuja is not isolation or a call for donor retreat, but for a new kind of solidarity. 

Donors can continue to play a critical role by investing with us to address pressing health needs, while building robust, resilient, and sustainable health infrastructure that supports countries in managing transitions away from perpetual dependence. The aim is not disengagement but transformation – from recipients of aid to equal partners.

Continental blueprint

The Accra gathering offered a continental blueprint for the future of health engagement with international partners. Nigeria’s September dialogue aimed to anchor it in national reality. Together, the two initiatives reflect a new mood: Africans insisting on authorship of their own health future. 

The rest of the world should welcome this. A sovereign Africa, healthier and stronger, is in the interest of humanity. 

Pandemics know no borders; health insecurity in one corner of the continent is insecurity everywhere in the world. Supporting Africa’s health sovereignty is not just about “helping countries,” it is also enlightened self-interest.

The Accra Summit and Nigeria’s dialogue point the way forward for Africa’s public health. To get there, we must act with urgency to strengthen South–South cooperation and collaboration, forging a continental alliance that harnesses shared expertise, resources, and innovation for collective health security. 

Unified vision

African Union leaders and Rwanda’s Ministry of Health signed an agreement to establish the African Medicines Agency’s first headquarters in Kigali, in June 2023. A single continental medicines agency will speed up approvals of medicines across the continent.

This pivotal moment calls for bold African leadership – one that articulates a unified vision and drives coordinated action on regional health priorities. At the core of this transformation is the creation of a dynamic health ecosystem that integrates the public and private sectors across the entire value chain – from research and development to manufacturing, distribution, and healthcare delivery. 

True health sovereignty will remain elusive until Africa establishes a vibrant intra-continental health market capable of producing, regulating, and procuring its own medical products and technologies. 

The African Continental Free Trade Area (AfCFTA) must serve as the backbone of this vision, enabling the seamless movement of health goods, services, and expertise across borders, unlocking economies of scale, and spurring investment in local industries. 

By taking these decisive steps, Africa can redefine its role in global health – emerging as a producer, innovator, and equal partner in shaping both the health of its people and the well-being of the world.

Dr Muhammad Ali Pate has been Nigeria’s Coordinating Minister of Health and Social Welfare since 2023. He was also the country’s Minister of State for Health between 2011 and 2013, prior to which he was the executive director of Nigeria’s National Primary Health Care Development Agency. He has also been a professor of public health leadership at Harvard University, and held various positions at the World Bank Group.

 

Image Credits: WHO, Nigeria Federal Ministry of Health and Welfare, Rwanda Ministry of Health.

Dental amalgam used to fill tooth cavities is set to be phased out by 2034 to reduce toxic exposures to mercury.

Mercury-containing dental amalgam, used to fill cavities, is set to be phased out globally by 2034 to reduce human exposure to the toxic heavy metal. The decision was taken by the 153 parties to the Minamata Convention on Mercury at the Sixth Conference of Parties (COP-6) that took place last week in Geneva.

While 50 countries, including the European Union’s 27 member states, have already phased out dental amalgam, typically a mix of liquid mercury and silver, many countries, including the United States, continue to allow the use of the amalgam in dental procedures. Mercury is a highly toxic element and exposure to even small quantities of it can cause developmental delays in children as well as affect the nervous, digestive and immune systems, according to the World Health Organization (WHO).

“Use of dental amalgam poses several challenges, including exposure to mercury of dental practitioners, also the cost challenges related to disposal of dental amalgam, and also mercury emissions from crematoria,” said Monika Stankiewicz, Executive Secretary of the Minamata Convention, a global treaty adopted in 2013 to protect both humans and the environment from the adverse effects of mercury. Alternatives to the amalgam include composite resin, glass ionomer, ceramics and gold.

Mercury in artisanal mining and cosmetics the focus of other COP6 initiatives

Countries that have phased out dental amalgam.

Stankiewicz spoke at a press conference on Monday, discussing the outcomes of COP6. Parties to the Convention also agreed to step up efforts to address mercury exposures in artisanal gold mining. They will also collaborate to reduce the availability of cosmetics with mercury. While such cosmetics are banned, they are available online, experts said. This year’s COP drew some 1000 in-person participants to Geneva as well as several thousand online.

The convention, named after the Japanese city of Minamata, alludes to the neurological disease that drew global attention to the issue in 1956, when several thousand Japanese residents of the city were diagnosed with symptoms of severe mercury poisoning, due to their consumption of fish and shellfish exposed to high methylmercury levels in wastewater emissions from a nearby chemical plant.

The Convention, adopted in 2013, came into force in 2017. Since the first Conference of the Parties in 2017, more restrictions on mercury use have progressively been added, based on the support and willingness of countries.

“The issue of dental amalgam has been discussed also in the past two COPs,” Stankiewicz said. “So, it’s a third COP that the parties have been negotiating the matter. And then each of the COPs, certain measures were adopted to dramatically reduce the use of dental amalgam. So, the convention already includes a number of measures that restrict the use.”

The decision to phase out dental amalgam worldwide received strong support from US Secretary of Health and Human Services Robert F Kennedy Jr, an environmental lawyer, who appeared before the COP’s opening session on 3 November via video link.

However, he also criticised the continued use of thiomersal, a preservative used in some vaccines that contains a derivative of mercury called ethylmercury.

“Why do we hold a double standard for mercury? Why do we call it dangerous in batteries, in over-the-counter medications, and makeup – but acceptable in vaccines and dental fillings,” Kennedy asked as the discussions kicked off on November 3. While the US FDA has recently banned the use of thiomersal, the WHO has continued to call it safe to use.

With regards to the phase out of amalgam, some countries at this year’s COP, including a bloc of African states, called for speeding up the timeline to ban the production, import and export of amalgam by 2030 – arguing that they lacked facilities to safely manage mercury waste. But they were met with resistance from other countries, including the United Kingdom and India, which considered the date as too ambitious. The UK allows for amalgam although its use is banned for children under the age of 15, pregnant or breastfeeding women.

Gold mining – a ‘just transition’

Crushing gold ore in Guinea before pouring in mercury and burning the mixture to produce pure gold.

Countries also discussed new measures to phase out mercury use in artisanal and small-scale gold mining – an occupation that continues to draw poor communities in developing countries, given the high price of gold.

The discussions took place just before the UN climate change conference (COP30) convened Monday (10-21 November) in the Amazonian city of Belém – one of the world’s regions where artisanal and small-scale gold mining exposes communities and the sensitive rain forest that they inhabit to dangerous levels of mercury emissions.

Artisanal gold extraction involves mixing mercury with crushed rocks of gold ore, then heating the amalgam to vaporize the mercury, leaving the gold behind. The process exposes workers, including women and children, to severe health risks through inhalation of mercury vapor, as well as releasing methylmercury into the environment, which can bioaccumulate in the food chain. 

Brenda Koekkoek, Senior Coordination Officer, Minamata Convention.

“The COP strengthened its commitment to addressing the challenges of artisanal and small-scale gold mining, otherwise referred to as ASGM, through acknowledging the need for a just transition for miners. So, this is supporting fair, inclusive and sustainable alternatives,” said Brenda Koekkoek, Senior Coordination Officer of the Minamata Convention.

While no specific decision was taken, parties to the convention agreed to support new technologies and other measures to phase out the use of mercury and related toxic exposures. This pathway, conference participants stressed, is preferable to banning ASGM altogether, which would turn the miners into criminals.

“This [discussion] does empower countries who have the mandatory obligation to develop national action plans under the Convention to consider measures of how they would look at the just transition (away from mercury use in artisanal mining) in their national action plans,” Koekkoek added.

WHO to help draw up a strategy for mercury phase-out in public health systems

Monika Stankiewicz, Executive Secretary, Minamata Convention.

For the next COP, scheduled in 2027, the WHO has been invited to prepare a strategy on mercury phase-out in cosmetics. This strategy would focus on advice to countries about measures to prevent the use, manufacture, import and export of mercury-contaminated cosmetics. “It could be then used domestically by parties, and also on that basis, prepare appropriate documentation to our COP in 2027,” Stankiewicz said.

WHO has been a longtime observer to the Convention, and historically active in measures such as phasing out mercury-containing thermometers and other medical devices used by health systems.

The parties to the convention also agreed to look more closely at the global mercury supply chain, sharing relevant information. An expert group has been constituted that would look more closely at the manufacture, use and trade in specific mercury compounds, as compared to elemental mercury, which has largely been the focus to date.

Image Credits: Unsplash/Navy Medicine, European Network for Environmental Medicine, Planet Gold .